Clinical Trials Browser

Phase 4 × tislelizumab × 90 days × Clear all

NCT07320105 2026-01-06

Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)

Phase 4 Recruiting

Carcinoma, Non-Small-Cell Lung